Item 5. OTHER INFORMATION

During the three months ended December 31, 2025, no director or officer (as defined in Rule 16a-1(f) of the Exchange Act) of the Company adopted, modified, or terminated a “Rule 10b5-1 trading agreement” or “non-Rule 10b5-1 trading agreement,” (each as defined in Item 408 of Regulation S-K of the Exchange Act), except as follows:

On November 13, 2025, Sherri Luther, the Company’s Chief Financial Officer, entered into a 10b5-1 trading arrangement (the “10b5-1 Plan”) for the sale of 12,000 shares of the Company’s common stock. The 10b5-1 Plan, scheduled to commence on February 12, 2026, is intended to satisfy the affirmative defense of Rule 10b5-1(c) and will terminate on August 19, 2026.

On November 21, 2025, Dr. Julie Eng, the Company’s Chief Technology Officer, entered into a 10b5-1 trading arrangement (the “10b5-1 Plan”) for the sale of 1,454 shares of the Company’s common stock and the potential sale of up to one hundred percent of the shares of Company common stock resulting from various performance share and restricted share award vesting in 2026 and 2027. The 10b5-1 Plan, scheduled to commence on February 20, 2026, is intended to satisfy the affirmative defense of Rule 10b5-1(c) and will terminate on March 5, 2027.

On November 21, 2025, Enrico DiGirolamo, the Chairman of the Company’s board, entered into a 10b5-1 trading arrangement (the “10b5-1 Plan”) for the sale of 2,272 shares of the Company’s common stock. The 10b5-1 Plan, scheduled to commence on August 31, 2026, is intended to satisfy the affirmative defense of Rule 10b5-1(c) and will terminate on September 1, 2026.

On December 3, 2025 Stephen Skaggs, a director on the Company’s board, entered into a 10b5-1 trading arrangement (the “10b5-1 Plan”) for the sale of 5,795 shares of the Company’s common stock. The 10b5-1 Plan, scheduled to commence on March 9, 2026, is intended to satisfy the affirmative defense of Rule 10b5-1(c) and will terminate on December 31, 2026.

On December 8, 2025, Jim Anderson, the Company’s Chief Executive Officer and a director on the Company’s board, entered into a 10b5-1 trading arrangement (the “10b5-1 Plan”) for the potential sale of a portion of the net shares of Company common stock resulting from the performance share award vesting on June 30, 2027. The 10b5-1 Plan, scheduled to commence on July 1, 2027, is intended to satisfy the affirmative defense of Rule 10b5-1(c) and will terminate on the earlier of (1) the date all the shares under the 10b5-1 Plan are sold or (2) December 1, 2027.